Some patients fear that they’ll lose access to tirzepatide because the US Food and Drug Administration determined that a shortage of the brand-name drug has ended – which means compounding of the medicine must stop.

Just like when you find a glitzy resort in your dream destination, your first question about weight loss drugs might be, how much is this going to set me back? Lucky for you, we’ve done our homework.

Only a fifth of large U.S. companies cover pricey GLP-1 weight-loss drugs like Wegovy and Zepbound in their health insurance plans, a new survey shows.

Less than a fifth of large employers in the U.S. include coverage for the popular but pricey weight loss drugs Wegovy and Zepbound, a KFF survey finds.

Compounding pharmacies are suing the Food and Drug Administration so they can keep making imitation versions of popular—and lucrative—tirzepatide drugs, namely knockoffs of Mounjaro for diabetes and Zepbound for weight loss.